Lixisenatide resensitizes the insulin‐secretory response to intravenous glucose challenge in people with type 2 diabetes – a study in both people with type 2 diabetes and healthy subjects
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Aims: Glucagon‐like peptide‐1 ( GLP ‐1) receptor agonists improve blood glucose control by enhancing glucose‐sensitive insulin release, delaying gastric emptying and reducing postprandial glucagon secretion. The studies reported here investigated the insulin response to an intravenous (iv) glucose challenge after injection of lixisenatide (LIXI) 20 µg or placebo. Methods: Two single‐centre, double‐blind, randomized, placebo‐controlled, single‐dose, crossover studies were performed in healthy subjects ( HS ) and people with type 2 diabetes mellitus ( T2DM ). Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge. Study endpoints included first‐ and second‐phase insulin response, insulin concentration (INS), glucagon response and glucose disposal rate ( K glucose ). LIXI exposure was measured over 12 h. Results: LIXI 20 µg reached maximum concentration after 2 h and resensitized first‐phase insulin secretion by 2.8‐fold in T2DM to rates comparable with those in HS on placebo, and raised second‐phase insulin secretion by 1.6‐fold in T2DM . INS rose correspondingly and glucose disposal was accelerated by 1.8‐fold in T2DM . First‐phase insulin secretion and glucose disposal were also augmented by LIXI in HS , whereas second‐phase insulin secretion reduced blood glucose concentrations to below fasting levels and then ceased, accompanied by a rapid, short‐lasting rise in glucagon. Otherwise, suppression of glucagon release subsequent to augmentation of insulin release was unaffected in T2DM and in HS . Conclusions: LIXI resensitized the insulin response to an iv glucose challenge in people with T2DM , thereby accelerating glucose disposal to nearly physiological intensity, and did not impair counter‐regulation to low glucose levels by glucagon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“The mechanism of action underlying the observed acute effects of LIXI on insulin secretion probably involves direct stimulation of GLP-1 receptors located in the pancreatic islet β-cells, resensitizing the glucose concentration-dependent exocytotic release from insulin-secretory vesicles via a cyclic AMP-dependent sig…”
BackgroundAbnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567 · cited 1×
“In healthy individuals, insulin secretion following a meal occurs in two distinct phases: a first phase that occurs during the first 10 min following a sudden rise in plasma glucose concentration, which reduces basal glucagon secretion and hepatic glucose production; and a second phase that is sustained until normogly…”
BackgroundInfluentialDiminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297 · cited 2×
“The GLP-1 receptor agonists, exenatide and liraglutide, both augment first- and second-phase insulin secretion in response to an intravenous (iv) glucose bolus [12,13].”
BackgroundRiddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172
Research works printed but not linked: 22
- 10.1111/j.1463-1326.2012.01663.x · DOI · Paper page
- 10.1152/physrev.00034.2006 · DOI · Paper page
- 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
- 10.1016/S0140-6736(06)69705-5 · DOI · Paper page
- 10.2337/diabetes.51.2007.S109 · DOI · Paper page
- 10.1007/s00125-002-0930-6 · DOI
- 10.1002/dmrr.198 · DOI · Paper page
- 10.2337/diabetes.52.7.1786 · DOI · Paper page
- 10.1111/dom.12121 · DOI · Paper page
- 10.2337/dc12-2462 · DOI · Paper page
- 10.1111/j.1463-1326.2012.01618.x · DOI · Paper page
- 10.1016/0169-2607(96)01755-5 · DOI · Paper page
- 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
- Rachman J, 1996, Normalization of insulin responses to glucose by overnight infusion of glucagon‐like peptide 1 (7–36) amide in patients with NIDDM, Diabetes, 45, 1524, 10.2337/diab.45.11.1524 · DOI · Paper page
- 10.1152/ajpendo.1997.273.5.E981 · DOI · Paper page
- 10.1152/ajpendo.2001.281.1.E155 · DOI · Paper page
- 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
- 10.1210/jc.2002-021545 · DOI · Paper page
- Ratner RE, 2009, Post‐meal pharmacodynamic profile of AVE0010, a once‐daily GLP‐1 receptor agonist, in patients with type 2 diabetes inadequately controlled on metformin (Abstract), Diabetologia, 52, S60
- Distiller LA, 2008, on behalf of the ACT6011 Study Group. Pharmacokinetics and pharmacodynamics of a new GLP‐1 agonist AVE0010 in type 2 diabetes patients [Abstract], Diabetes, 57, A154
- 10.1016/j.regpep.2013.04.001 · DOI · Paper page
- 10.1111/j.1463-1326.2011.01452.x · DOI · Paper page
Cited by
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
Metadata
- Authors
- Becker, R. H. A., Stechl, J., Msihid, J., & Kapitza, C.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-03-25
- Volume
- 16
- Issue
- 9
- Pages
- 793-800
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2050250967
- Cited by
- 25
- References
- 14
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.